In addition, we conducted a bivariate analysis of CD34 and CD38 expression by traditional gating for each patient and found that LSCs (CD34+CD38-) represented on average 26% of the CD25+ AML population (Figure 4C). This evidence concerns the gene CD38 and acute myeloid leukemia.